COMPOSITION: Clarithromycin 250 mg
Clarithromycin (Macrolide antibiotics)
Mode of Action:
- It is a broad spectrum macrolide antibacterial agent active in vitro and effective in vivo against the major pathogens responsible for respiratory tract infections in immunocompetent patients.
- Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunits of susceptible organisms and inhibiting protein synthesis.
- Shown to penetrate macrophages and leukocytes, which makes them particularly effective against intracellular pathogens such as Legionella pneumophila and Chlamydia species.
- In addition to its antimicrobial activity, the drug stimulates cellular host defense mechanisms involving the activation of protein kinase C.
- Clarithromycin is absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability of 250 mg tablets is approximately 50%.
- Clarithromycin is metabolized in the liver and the stomach.
Comparative to other drugs:
- Clarithromycin provides similar clinical and bacteriological efficacy to that seen with beta-lactam agents, cephalosporins, and other macrolides.
- Pharmacokinetic profiles superior to that of erythromycin.
- Shows equal efficacy and better tolerability as compared to erythromycin in the treatment of community-acquired pneumonia.
- Clarithromycin twice daily is as effective and as well tolerated as penicillin in the treatment of streptococcal pharyngitis.
- Hypersensitivity to macrolide antibiotic drugs or any of its excipients Clarithromycin should not be given to patients with a history of ventricular cardiac arrhythmia.
Clarithromycin 250 mg
- Acute streptococcal pharyngitis/ Acute exacerbation of chronic bronchitis
- Community-acquired pneumonia
- Uncomplicated skin and skin structure infections
- Bacterial exacerbation of chronic bronchitis